title: Retinal prosthetics, optogenetics, and chemical photoswitches.
abstract: Three technologies have emerged as therapies to restore light sensing to profoundly blind patients suffering from late-stage retinal degenerations: (1) retinal prosthetics, (2) optogenetics, and (3) chemical photoswitches. Prosthetics are the most mature and the only approach in clinical practice. Prosthetic implants require complex surgical intervention and provide only limited visual resolution but can potentially restore navigational ability to many blind patients. Optogenetics uses viral delivery of type 1 opsin genes from prokaryotes or eukaryote algae to restore light responses in survivor neurons. Targeting and expression remain major problems, but are potentially soluble. Importantly, optogenetics could provide the ultimate in high-resolution vision due to the long persistence of gene expression achieved in animal models. Nevertheless, optogenetics remains challenging to implement in human eyes with large volumes, complex disease progression, and physical barriers to viral penetration. Now, a new generation of photochromic ligands or chemical photoswitches (azobenzene-quaternary ammonium derivatives) can be injected into a degenerated mouse eye and, in minutes to hours, activate light responses in neurons. These photoswitches offer the potential for rapidly and reversibly screening the vision restoration expected in an individual patient. Chemical photoswitch variants that persist in the cell membrane could make them a simple therapy of choice, with resolution and sensitivity equivalent to optogenetics approaches. A major complexity in treating retinal degenerations is retinal remodeling: pathologic network rewiring, molecular reprogramming, and cell death that compromise signaling in the surviving retina. Remodeling forces a choice between upstream and downstream targeting, each engaging different benefits and defects. Prosthetics and optogenetics can be implemented in either mode, but the use of chemical photoswitches is currently limited to downstream implementations. Even so, given the high density of human foveal ganglion cells, the ultimate chemical photoswitch treatment could deliver cost-effective, high-resolution vision for the blind.
authors.affiliation: Department of Ophthalmology, University of Utah School of Medicine , Salt Lake City, Utah 84132, United States.
authors.forename: Robert
authors.initials: R
authors.lastname: Marc
authors.forename: Rebecca
authors.initials: R
authors.lastname: Pfeiffer
authors.forename: Bryan
authors.initials: B
authors.lastname: Jones
mesh_terms: D000818:Animals; D006801:Humans; D062308:Optogenetics / Q000379:methods*; D012160:Retina / Q000503:physiopathology; D012162:Retinal Degeneration / Q000503:physiopathology / Q000628:therapy*; D057488:Visual Prosthesis
keywords: Retinal degeneration; blindness; chemical photoswitches; optogenetics; prosthetics; remodeling; reprogramming
references.citation: Science. 2002 Feb 8;295(5557):1022-5
references.pmid: 11834821
references.citation: Neuron. 2014 Feb 19;81(4):800-13
references.pmid: 24559673
references.citation: Nat Neurosci. 2008 Jun;11(6):667-75
references.pmid: 18432197
references.citation: Mol Vis. 2008 Apr 25;14:782-806
references.pmid: 18483561
references.citation: Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13940-5
references.pmid: 14615590
references.citation: Surv Ophthalmol. 2002 Jul-Aug;47(4):335-56
references.pmid: 12161210
references.citation: Nat Genet. 1998 Dec;20(4):344-51
references.pmid: 9843205
references.citation: Prog Neurobiol. 2014 Jan;112:1-23
references.pmid: 24184323
references.citation: PLoS One. 2014 May 22;9(5):e97182
references.pmid: 24853376
references.citation: Nat Methods. 2008 Apr;5(4):331-8
references.pmid: 18311146
references.citation: N Biotechnol. 2013 Jun 25;30(5):461-74
references.pmid: 23664865
references.citation: J Neurophysiol. 2008 Mar;99(3):1408-21
references.pmid: 18216234
references.citation: Proc Biol Sci. 2013 Feb 20;280(1757):20130077
references.pmid: 23427175
references.citation: Prog Retin Eye Res. 2003 Sep;22(5):607-55
references.pmid: 12892644
references.citation: Vision Res. 2003 Apr;43(8):867-77
references.pmid: 12668056
references.citation: Methods Mol Biol. 2011;807:179-218
references.pmid: 22034031
references.citation: Science. 2010 Jul 23;329(5990):413-7
references.pmid: 20576849
references.citation: Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15012-7
references.pmid: 22891310
references.citation: Science. 2000 May 26;288(5470):1390-6
references.pmid: 10827943
references.citation: Methods Mol Biol. 2014;1148:149-60
references.pmid: 24718800
references.citation: Gene Ther. 2012 Feb;19(2):169-75
references.pmid: 21993174
references.citation: J Neural Eng. 2014 Feb;11(1):016007
references.pmid: 24654269
references.citation: Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):16009-14
references.pmid: 18836071
references.citation: J Clin Invest. 2010 Sep;120(9):3042-53
references.pmid: 20811160
references.citation: PLoS One. 2013;8(3):e57676
references.pmid: 23472098
references.citation: Nat Biotechnol. 2013 Aug;31(8):741-7
references.pmid: 23873086
references.citation: J Neurosci. 2008 Jun 18;28(25):6526-36
references.pmid: 18562624
references.citation: Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3364-71
references.pmid: 17591910
references.citation: Front Syst Neurosci. 2012 Feb 24;6:8
references.pmid: 22383900
references.citation: Invest Ophthalmol Vis Sci. 2013 Nov 19;54(12):7658-65
references.pmid: 24150759
references.citation: Vision Res. 1985;25(12):1795-810
references.pmid: 3832605
references.citation: Nature. 1989 Oct 19;341(6243):643-6
references.pmid: 2797190
references.citation: IEEE Trans Biomed Eng. 2003 Jul;50(7):881-9
references.pmid: 12848356
references.citation: J Neurosci. 2002 Jan 15;22(2):413-27
references.pmid: 11784786
references.citation: J Comp Neurol. 2003 Sep 8;464(1):1-16
references.pmid: 12866125
references.citation: PLoS One. 2014 Jan 28;9(1):e86253
references.pmid: 24489706
references.citation: J Comp Neurol. 2011 Oct 1;519(14):2713-33
references.pmid: 21681749
references.citation: Prog Retin Eye Res. 2013 Sep;36:1-23
references.pmid: 23500412
references.citation: Mol Neurodegener. 2012 Feb 10;7:7
references.pmid: 22325330
references.citation: Sci Transl Med. 2013 Nov 6;5(210):210ps16
references.pmid: 24197733
references.citation: ACS Chem Neurosci. 2011 Sep 21;2(9):536-43
references.pmid: 22860175
references.citation: Exp Eye Res. 2012 May;98:88-96
references.pmid: 22685713
references.citation: J Comp Neurol. 2000 Oct 2;425(4):560-82
references.pmid: 10975880
references.citation: FASEB J. 2012 Jan;26(1):81-92
references.pmid: 21940995
references.citation: Nat Genet. 2001 May;28(1):92-5
references.pmid: 11326284
references.citation: J Neurosci. 2014 Apr 2;34(14):4871-81
references.pmid: 24695706
references.citation: Neuron. 2012 Jul 26;75(2):271-82
references.pmid: 22841312
references.citation: J Neurosci. 2002 Jul 1;22(13):5492-504
references.pmid: 12097501
references.citation: JAMA Ophthalmol. 2013 Feb;131(2):183-9
references.pmid: 23544203
references.citation: Gene Ther. 2012 Feb;19(2):176-81
references.pmid: 22011645
references.citation: Br J Ophthalmol. 2005 Oct;89(10):1258-64
references.pmid: 16170112
references.citation: Mol Ther. 2011 Jul;19(7):1220-9
references.pmid: 21505421
references.citation: Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2263-8
references.pmid: 19933186
references.citation: Am J Ophthalmol. 2014 Jun;157(6):1282-90
references.pmid: 24560994
references.citation: Nature. 2007 Apr 5;446(7136):633-9
references.pmid: 17410168
references.citation: Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18476-81
references.pmid: 22042849
references.citation: Front Neural Circuits. 2013 Feb 18;7:17
references.pmid: 23423628
references.citation: Jpn J Ophthalmol. 2012 Jul;56(4):289-306
references.pmid: 22644448